overcoming resistance to car-t therapy in cll with ibrutinib & venetoclax
Published 1 year ago • 237 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
2:43
mechanisms of resistance to car-t therapy in lymphoma & potential strategies to overcome these
-
3:12
an insight into resistance mechanisms of cll cells to car-t therapy
-
1:39
current situation of car-t therapy for cll
-
2:43
resistance to car t-cell therapy
-
0:56
key challenges in developing car-t therapy for cll
-
4:04
immunotherapy & car t cells: part 2
-
15:22
improving car-t cell therapies (immunotherapy documentary part iii)
-
2:14
manufacturing car-t cell therapies: the novartis approach
-
1:38
challenges of car-t therapy in the real-world setting
-
2:33
promising strategies to optimize car-t therapy in all
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
1:10
tackling resistance to car-t therapy across hematological malignancies
-
2:49
novel strategies to optimize car-t therapy in myeloma
-
1:46
car-t as a next-generation therapy for cll
-
4:04
overcoming challenges in car t-cell therapy for multiple myeloma
-
3:02
the challenges of using car-t cell therapy to treat patients with cll
-
1:31
strategies to minimize the occurrence of crs and icans in patients treated with car-t therapy
-
6:59
management strategies for early and late infections in patients undergoing car-t cell therapy
-
2:07
challenges with the preparation and administration of car-t therapy
-
2:47
current challenges with car t-cell therapy
-
1:23
moving car-t therapy to the outpatient setting
-
3:31
the role of lymphodepletion in car t-cell therapy: current knowledge & the need for personalization